Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

Award Number: R44CA287806
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/21/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2025
AWARD TERMINATION DATE: 01/09/2026

Group Awards By:

View Award Description

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) - PROJECT SUMMARY / ABSTRACT There are more than 230,000 new cases of lung cancer and over 130,000 deaths due to lung cancer each year in the U.S. Approximately 120,000 people each year will present with metastatic Non-Small Cell Lung Cancer (mNSCLC) for the first time, and only 7% of these patients will survive five years or more. accurius is developing the first of a kind inhalable agent that will be a safe and highly effective treatment for mNSCLC and other cancers metastatic to the lung. The agent is an engineered oncolytic virus based on the Influenza A virus (eIAV) which will selectively infect and destroy cancer cells while sparing healthy cells and induce the body’s own anti-tumor immune response. This treatment will dramatically improve overall survival rates for the metastatic NSCLC patient population as well for the 50,000 patients each year with different tumor types that have their cancer metastasize to the lung. Phase I of the accurius project will determine the top two eIAV candidates in the accurius pipeline, each of which must improve median survival time by more than 50% versus the control arm in animal models while showing significant ability to elicit the natural immune response to the presence of the tumors. Follow-up testing will determine if either or both of the candidates can improve median survival time by an additional 25% in combination with an immune checkpoint blocker. Phase II will finalize the cell culture-based manufacturing process for the candidate(s) which passed both tests in phase I and also optimize their inhalable form. The inhalable forms will then have to pass the same efficacy and natural immune response stimulation tests as in Phase I as well as demonstrating safety in animal models without tumors in order to proceed to further clinical testing in humans. The potential realizable market for accurius’s safe, inhalable, effective eIAV is over 100,000 metastatic lung cancer patients annually in the US alone, the vast majority of whom will not respond to currently available treatments and face dismal survival prospects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	001	2	2/9/2026	TERMINATION	$0
2026	2024	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	000	2	1/9/2026	TERMINATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	000	1	3/18/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $1,000,000 )
2024	2024	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	002	2	9/4/2024	EXTENSION WITH OR WITHOUT FUNDS	$1,000,000
2024	2023	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	001	1	9/4/2024	NEW	$0
2024	2023	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	000	1	11/13/2023	NEW	$0
														Subtotal = $1,000,000

Issue Date FY: 2023 ( Subtotal = $399,999 )
2023	2023	ACCURIUS THERAPEUTICS, INC.	213 EAST ST	LEXINGTON	MA	02420	MIDDLESEX	USA	Cancer Treatment Research	000	1	9/21/2023	NEW	$399,999
														Subtotal = $399,999

Grand Total All Awards = $1,399,999

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)

Award Number: R44CA287806

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/21/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2025

AWARD TERMINATION DATE: 01/09/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer